Patient profile - Vidya
Would you agree that early intervention may protect patients like Vidya by reducing CV risk?
Vidya, 55
This material contains AI-generated content.
T2D
Uncontrolled hypertension, hypercholesterolaemia, overweight (BMI 29)
Lifestyle changes, ACEi, statin, metformin
76
Not tested
133/84
8%
Medical considerations | |
|---|---|
Not at goal with metabolic control. |
|
What would happen if JARDIANCE® is not initiated at the age of 60?
Vidya, 60
This material contains AI-generated content.
T2D + eCVD
Uncontrolled hypertension, hypercholesterolaemia, CAD, overweight (BMI 29)
ACEi, statin, metformin + DPP4i
74
30
140/90
7.4%
Medical considerations | |
|---|---|
Close to goal with metabolic control. However, not at goal with BP control and diagnosed with cardiovascular disease. |
|
What would happen if JARDIANCE® is not initiated at the age of 65?
Vidya, 65
This material contains AI-generated content.
T2D with CVD and CKD
T2D, uncontrolled hypertension, hypercholesterolaemia, CAD, overweight (BMI 29), early signs of HF
ACEi, statin, metformin, DPP-4i
57
320
136/78
7.2%
Medical considerations | |
|---|---|
Kidney function declined by 25% over the last 10 years. |
|
Consider early intervention with JARDIANCE® for interrelated CRM conditions to help protect your patients like Vidya by slowing disease progression and reducing risk.1
Prescribe JARDIANCE® as early, foundational T2D treatment1
-
API dated 19th Jul 2024 (Based on JARDIANCE® approved prescribing information dated 18th Jul 2024).
-
Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms. Diabetes Care. 2010;33(2):442-449.
-
Ma C-X, Ma X-N, Guan C-H, Li Y-D, Mauricio D, Fu S-B. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(74):1-15.
-
American Diabetes Association. Cardiovascular disease. Accessed September 25, 2024. https://diabetes.org/about-diabetes/complications/cardiovascular-disease
-
ACEi, angiotensin-converting enzyme inhibitor; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; CRM, cardio-renal-metabolic; CV, cardiovascular; DPP-4i, dipeptidyl peptidase-4 inhibitor; CVD, cardiovascular disease; eCVD, established cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HF, heart failure; PCP, primary care physician; RAASi, renin-angiotensin-aldosterone system inhibitor; T2D, type 2 diabetes; uACR, urine albumin-to-creatinine ratio.
PC-IN-103695